Related references
Note: Only part of the references are listed.Evaluation of eight different bioinformatics tools to predict viral tropism in different human immunodeficiency virus type 1 subtypes
Carolina Garrido et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2008)
Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile Virus infection: A meta-analysis of 4 cohorts in the US epidemic
Jean K. Lim et al.
JOURNAL OF INFECTIOUS DISEASES (2008)
Hepatotoxicity observed in clinical trials of aplaviroc (GW873140)
W. G. Nichols et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry
Mike Westby et al.
JOURNAL OF VIROLOGY (2007)
Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism
Jeannette M. Whitcomb et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Emergence of CXCR4-Using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-Infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir
M Westby et al.
JOURNAL OF VIROLOGY (2006)
G-protein-coupled receptor-protein interactions: Basis for new concepts on receptor structure and function
N Tilakaratne et al.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2005)
Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1
G Fätkenheuer et al.
NATURE MEDICINE (2005)
Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity
P Dorr et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Chemokine receptor CCR5 promotes leukocyte trafficking to the brain and survival in West Nile virus infection
WG Glass et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV
DK Walker et al.
DRUG METABOLISM AND DISPOSITION (2005)
Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41
L Xu et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Intrinsic obstacles to human immunodeficiency virus type 1 coreceptor switching
C Pastore et al.
JOURNAL OF VIROLOGY (2004)
High frequency of syncytium-inducing and CXCR4-tropic viruses among human immunodeficiency virus type 1 subtype C-infected patients receiving antiretroviral treatment
ER Johnston et al.
JOURNAL OF VIROLOGY (2003)
Early viral load and CD4+ T cell count, but not percentage of CCR5+ or CXCR4+ CD4+ T cells, are associated with R5-to-X4 HIV type 1 virus evolution
RP Van Rij et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2003)
Share Paper
